Associated Genetic Biomarkers
Phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit delta (PIK3CD) is a gene that encodes a protein that function in the immune response and the phosphorylation of inositol lipids. Missense mutations, nonsense mutations, silent mutations, and frameshift insertions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
PIK3CD is altered in 1.35% of all cancers with colon adenocarcinoma, conventional glioblastoma multiforme, lung adenocarcinoma, breast invasive ductal carcinoma, and prostate adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in PIK3CD are PIK3CD Mutation (0.66%), PIK3CD Loss (0.20%), PIK3CD Amplification (0.03%), PIK3CD E1021K (0.02%), and PIK3CD R300C (0.02%) .
PIK3CD status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains PIK3CD status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with PIK3CD status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is PIK3CD Mutation .
Paxalisib and radiation therapy are the most frequent therapies in trials with PIK3CD as an inclusion criteria .
Significance of PIK3CD in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.